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History-Adjusted Marginal Structural Models:
Time-Varying Effect Modification
Maya L. Petersen and Mark J. van der Laan
Abstract
Marginal structural models (MSM) provide a powerful tool for estimating the
causal effect of a treatment, particularly in the context of longitudinal data struc-
tures. These models, introduced by Robins, model the marginal distributions of
treatment-specific counterfactual outcomes, possibly conditional on a subset of
the baseline covariates. However, standard MSM cannot incorporate modifica-
tion of treatment effects by time-varying covariates. In the context of clinical
decision- making such time-varying effect modifiers are often of considerable in-
terest, as they are used in practice to guide treatment decisions for an individual.
In this article we introduce a generalization of marginal structural models, which
we call history-adjusted marginal structural models (HA-MSM). These models
allow estimation of adjusted causal effects of treatment, given the observed past,
and are therefore more suitable for making treatment decisions at the individual
level and for identification of time-dependent effect modifiers. We provide a prac-
tical introduction to HA-MSM relying on an example drawn from the treatment
of HIV, and discuss parameters estimated, assumptions, and implementation using
standard software.
1 Introduction.
Marginal structural models (MSM), introduced by Robins, (e.g., Robins
(2000), Robins (1999), and van der Laan and Robins (2002)), represent a
major advance in the statistical methodology for causal inference. In epidemi-
ological and clinical research, subjects are often followed over time and longi-
tudinal data on treatment status and covariates collected. When treatment
status can change over time, conventional analytic approaches (such as stan-
dard multivariable regression methods) often fail to allow valid causal infer-
ences about the effect of treatment. Marginal structural models address this
well-recognized problem. In addition, in longitudinal studies many covariates
are often collected over multiple time points, resulting in a high-dimensional
modelling problem in which likelihood-based estimation approaches can be
highly susceptible to model misspecification. Marginal structural models of-
fer alternative estimators of causal effects that focus on the causal parameter
of interest, increasing robustness to misspecification of other parts of the like-
lihood. As a result, in many research contexts marginal structural models
are the best available analytic method.
Marginal structural models to date have been restricted to the estimation
of the causal effects of treatment or exposure conditional on baseline covari-
ates. Thus it has been possible to use this methodology to address questions
such as ”What is the effect of a treatment and how does it differ between
study members with different covariate values at entry to the study?”, but
not ”How does the effect of a treatment differ as a result of changing val-
ues of a covariate over the course of the study?”. In other words, it has
not been possible to use MSM to estimate modification of causal effects by
time-dependent covariates. In many research settings, estimation of time-
dependent effect modification is of major interest. In clinical settings in
particular, treatment decisions are often modified over time as a result of
changing values of a patient’s covariates. Estimation of how past values of
these covariates modify the future causal effect of a treatment has important
implications for understanding the mechanistic action of the treatment, as
well as guiding clinical decision-making.
In this paper we introduce a generalization of MSM to allow estimation of
effect modification by time-varying covariates, which we call history-adjusted
marginal structural models (HA-MSM). The aim of the paper is to provide
a practical and intuitive understanding of this new methodology- the formal
statistical theory is presented in a companion paper. Here, we provide a non-
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technical discussion of the assumptions underlying this method and discuss
implementation using standard software and interpretation of results. We
rely throughout the paper on an example drawn from the treatment of Human
Immunodeficiency Virus (HIV) to illustrate our notation and results.
2 Example: Antiretroviral therapy for the
treatment of HIV infection.
Antiretroviral therapy (ART) is able to suppress HIV replication to an extent
that virus in the patient’s blood, as measured by plasma HIV RNA level
(viral load), becomes undetectable. Unfortunately, the virus infecting many
treated individuals eventually develops resistance to the drug regimen being
used, resulting in a rebound of viral load to detectable levels (Ledergerber
et al. (1999), Lucas et al. (1999)). Viral rebound is frequently followed by
a decline in immunologic function, as reflected by CD4 T-cell count, and by
disease progression if the patient is not switched to a new therapy regimen
that is able to re-suppress the virus (Panel on Clinical Practices for Treatment
of HIV infection (2004)).
In contrast, some patients maintain stable CD4 T-cell counts over time,
despite loss of virologic suppression (Deeks et al. (2002)). One hypothesis ad-
vanced to explain this phenomenon is that mutations necessary to confer viral
resistance to some types of antiretroviral drugs result in a loss of viral fitness,
and as a result, a reduced ability of the virus to deplete CD4 T-cells (Deeks
(2001)). Over time, the virus may accumulate additional compensatory mu-
tations that help restore viral fitness. In this article we address whether the
presence of certain resistance mutations, which emerge over time, can modify
the effect of future non-suppressive antiretroviral treatment on CD4 T-cell
count depletion. Demonstration of such time-dependent effect modification
would have important clinical consequences, suggesting that data on viral
resistance mutations could help inform decisions about when to switch anti-
retroviral therapy regimen in patients with incomplete virologic suppression.
In order to address this question, we use data from a cohort of HIV-
infected patients currently treated with ART. Subjects become eligible for
our analysis when their viral load rebounds to a detectable level. Data on
covariates and treatment are collected on each subject throughout the study
until follow-up ends at time K+1. Covariates at time t are denoted L(t), t =
2
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0, ..., K + 1, and include CD4 T-cell count, the outcome of interest, denoted
Y(t), and viral mutation profile, denoted S(t). For the sake of exposition,
we treat S(t) here as a binary variable, denoting the presence or absence
of a set of key viral mutations thought to affect fitness. Of course, one
could also make S(t) a vector, where each component is an indicator that
a given mutation is present. this type.Treatment status is a binary variable
indicating whether a subject has switched off of his or her original non-
suppressive ART regimen or not, and is denoted A(t), t = 0, ..., K. Thus,
the data observed on each randomly sampled subject can be written: O =
(L(0), A(0), . . . , L(K), A(K), L(K + 1)), where we assume L(t) is measured
before A(t). For pedagogical purposes, we assume that variables are discrete
valued, and that a subject can only switch to a new therapy once; we define
A(t) = 1 as long as a subject remains on his/her original treatment regimen,
and let A(t) jump to 0 and remain there as soon as a subject switches to a
new treatment. The method can be easily extended, however, to encompass
more complex treatment patterns.
3 Marginal Structural Models and the coun-
terfactual framework for causal inference
Marginal structural models are based on a counterfactual definition of casual
effects. A counterfactual outcome is defined as the outcome that would have
been observed for a given individual under a specific treatment, whether or
not the individual did in fact receive that treatment. In the counterfactual
framework, the causal effect of a treatment regimen on an individual is de-
fined as the difference in that individual’s counterfactual outcome if he/she
received the treatment regimen vs. did not receive the treatment regimen.
Marginal structural models are models of how the population distribution of
these counterfactual outcomes changes as result of changes in treatment.
Introduction of some standard notation used in marginal structural mod-
els helps to define the assumptions on which they are based. We denote a
time-dependent process X(t), measured sequentially over time from the be-
ginning of the study to time t, as X¯(t). We thus denote treatment over the
course of the study (t = 0, ..., K) as A¯(K) = (A(0), ..., A(K)), and covari-
ates measured over the course of the study L¯(K + 1). We use A to denote
all possible longitudinal treatment regimens, and A(t) to denote all possi-
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ble longitudinal treatment regimens through time t. Finally, we use L¯a¯(t)
to denote a counterfactual covariate process, consisting of the values of all
measured covariates up till time t that would have been observed if a subject
had followed a treatment regimen A¯ = a¯.
Marginal structural models assume that the outcome or covariate process
we observe for each individual is equivalent to the counterfactual outcome
or covariate process for that individual under the treatment regimen he/she
actually received (Consistency Assumption: O = (A¯(K), L¯A¯(K+1))). Under
this assumption, causal inference can be treated as a missing data problem. If
no data were missing, we would observe for each individual the counterfactual
covariate process he/she would have followed under each possible treatment
regimen. If we had access to these full data we could use them to fit the
marginal structural model defining our causal effect of interest. Instead,
the observed data consist only of each individual’s covariates under his/her
observed treatment regimen.
Marginal structural models are thus defined using the full counterfactual
data, but must be estimated using the observed data. In order to make
them identifiable, we assume sequential randomization of the treatment with
respect to subject’s past measured covariates (Sequential Randomization As-
sumption: A(t)⊥Ya¯|A¯(t − 1), L¯(t), t = 0, ..., K). Under the sequential ran-
domization assumption (SRA), treatment assignment at each time point is
allowed to depend on any measured characteristics of the subject’s past at
that time point, but not on any unmeasured characteristics that also affect
outcome. In other words, there must be no unmeasured confounders of the
effect of treatment on outcome.
Finally, we assume that the counterfactual values of covariates cannot
be affected by treatment that occurs after they are measured (Temporal
Ordering Assumption: La¯(t) = La¯(t−1)(t)).
Applied to our HIV example, A¯(K) is a vector of binary variables, con-
sisting of one for each time point until a subject switches therapy, and zero
thereafter. For each possible time until switching, (L¯a¯(t)(K + 1)) denotes
the counterfactual CD4 T-cell counts, viral load, mutations, etc. over time
that would have been observed if the subject had switched therapy at the
time implied by A¯ = a¯. The full data for an individual thus consist of
XFull = (L¯a¯(K + 1), a¯ ∈ A). Our outcome of interest for a given time point
t is the counterfactual CD4 T-cell count measured m months in the future
under the switching time indicated by a¯, denoted Ya¯(t+m). Under the tem-
poral ordering and consistency assumptions, the observed data for a subject
4
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can be represented as his/her actual switch time and the counterfactual CD4
T-cell count, viral mutation process, etc. corresponding to that switch time.
In addition, we assume that there are no unmeasured variables that predict,
at any time point, both probability of switching treatment and also final CD4
T-cell count (the SRA).
4 Definition of history-adjusted marginal struc-
tural models: What do HA-MSM estimate?
HA-MSM model some parameter of the counterfactual outcome if the study
population were to follow their observed treatment history up till time j,
followed by a specified counterfactual future treatment history until outcome
is measured, conditional on a subset of (possibly time-varying) covariates
and/or treatment history measured before time j. In this article, we will focus
on HA-MSM concerned with the mean of these counterfactual outcomes;
however, the same framework can be readily adopted to model the median or
any other parameter. Before we discuss the interpretation of this parameter,
we introduce some final notation to facilitate its formal definition.
We denote a future longitudinal treatment regimen, beginning at time
j and continuing until the outcome is measured m time points later, as
a(j, j+m− 1) ≡ (a(j), a(j+1), . . . , a(j+m− 1)), for j = 0, . . . , K +1−m.
Let V (j) ⊂ (L¯(j), A¯(j−1)) be a subset of a subject’s treatment and covariate
history up till time j. For each time point in the study for which the outcome
m time points later is defined, j = 0, . . . , K + 1−m, HA-MSM model some
parameter of the counterfactual outcome YA¯(j−1),a(j,j+m−1)(j+m), conditional
on V (j), under each possible future treatment regimen. We note that, in the
case that the set of possible future treatment regimens beginning at time
j depends on a subject’s treatment history up till time j, we must include
treatment history in the subset of a subject’s past on which we condition
(A¯(j − 1) ⊂ V (j)), so that the set of possible future treatments is the same
for all subjects with a given V (j) value . For example, if only a single change
in treatment is allowed over the course of the study, whether or not such a
treatment has already occurred will restrict whether or not it can occur in the
future, and so when considering counterfactuals indexed by possible future
switch times, we must condition on a subject not having already switched
treatment.
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HA-MSM in this paper are concerned with inference for the following
parameter:
E0(YA¯(j−1),a(j,j+m−1)(j +m) | V (j)), j = 0, . . . , K + 1−m (1)
where subscript 0 denotes the true parameter value.
To clarify both the notation and the interpretation of this parameter, we
rely again on our HIV example. Future antiretroviral treatment after time
j until outcome is measured, denoted a(j, j +m− 1), consists of a vector of
treatment decisions (a(j), . . . , a(j+m− 1))), where a(t) = 0 if a subject has
switched treatment at or before time l, and otherwise a(t) = 1. This vector
of future treatment decisions exists for each subject beginning at each time
point j = 0, . . . , K + 1−m.
We summarize a(j, j+m−1) as c(j) ≡ ∑j+m−1l=j a(l), which represents the
future time (after time point j) that the subject will spend on his/her original
failing therapy before either switching or the outcome is measured. The viral
mutation profile at time j (presence or absence of mutations affecting viral
fitness) is denoted S(j), a subset of the full covariate history measured over
time, L¯(j). For each time point j, we are interested in the mean counter-
factual CD4 T-cell counts m months later among individuals who have not
yet switched therapy, if they were to follow their observed treatment history
up till time j (not switching), and then switch therapy at a specified time
after j. In addition, we are interested in how these counterfactual CD4 T-cell
counts may differ depending on the presence of key viral mutations at time
j.
For example, for j = 6
E0
(
YA¯(5)=1,c(6)=0(6 +m) | A¯(5) = 1, S(6) = 1
)
, (2)
denotes the mean counterfactual CD4 T-cell count m months later among
the subgroup of individuals who have not switched therapy and who have
key viral mutations present at time point 6, if that subgroup had followed
its observed treatment history through time 5 (not switching), and then
switched therapy at time 6. If we knew the counterfactual outcomes under an
immediate switch of treatment for every member of this subgroup, we could
simply take the mean of these outcomes. However, in the observed data, we




Although the assumptions outlined above ensure that our counterfactuals
of interest are identifiable from the observed data, in most settings the high
dimensions of the data require that we assume some model for (1) to make
estimation feasible using finite sample sizes. In other words, to reduce the
dimensions of the problem we assume some model for the dependence of the
counterfactual outcome on future and past treatment regimens, conditional
on a subset of the observed past. Formally, we assume a model
mβ0(j, a(j, j +m− 1) | V (j)) for our parameter of interest
E0(YA¯(j−1),a(j,j+m−1)(j+m) | V (j)), j = 0, . . . , K+1−m. The model adopted
is flexible and should be driven by our knowledge of the subject matter. To
illustrate one potential model, we return to our HIV example.
Recall that we are interested in answering the question “Given a subject’s
current viral mutation profile and the length of time he/she has already
spent on non-suppressive ART, how does additional time on non-suppressive
therapy affect CD4 T-cell count m months later?”. We hypothesize that
the effect of future time until switching will differ depending on a subject’s
current viral mutation profile; in the presence of mutations that restore viral
fitness, non-suppressive therapy is hypothesized to result in a faster depletion
of CD4 T-cells. We further hypothesize that the effect of future time until
switching will differ depending how long a subject has already spent on non-
suppressive therapy.
To address these questions, we might assume the following model :
E0(YA¯(j−1),a(j,j+m−1)(j +m) | A¯(j − 1), S(j))
= I(A(j − 1) = 1)(β0 + β1 ∗ c(j) + β2 ∗ S(j) + β3 ∗ j + β4 ∗ c(j) ∗ S(j) + β5 ∗ c(j) ∗ j), (3)
j = 0, . . . , K + 1 −m. In other words, we might assume that, among indi-
viduals who have not yet switched treatment (A(j − 1) = 1), counterfactual
CD4 T-cell count m months later depends linearly on additional time un-
til switching (c(j)), but the magnitude of this effect may differ depending
on the duration a patient has already spent on non-suppressive therapy (j)
and the current mutation profile of the HIV virus (S(j)). This model allows
us to estimate the effect of each additional month until switching to a new
therapy on CD4 T-cell count m months later, among patients who have been
on their current non-suppressive therapy for different durations, and among
patients infected with virus that does and does not harbor key mutations.
For example, by testing whether β4 = 0 we are testing our hypothesis that
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the causal effect of increased future exposure time differs depending on a
subject’s current viral mutation profile.
5 Implementation of HA-MSM: the Inverse
Probability of Treatment Weighted estima-
tor.
Several HA-MSM estimators are available; here, we focus on the Inverse
Probability of Treatment Weighted (IPTW) estimator, which can be imple-
mented using standard software. The IPTW estimator can be understood as
simply a weighted least squares estimator. For each time point j in the study,
each subject receives a weight. The denominator of this weight is informally
the subject’s probability of receiving the treatment that he or she actually
received, from time point j until the outcome is measured. If a subject has
a longitudinal treatment regimen beginning at time point j that occurs fre-
quently in the data among subjects with his/her covariate and treatment
history, he/she receives a small j-specific weight. In contrast, if the subject
has an unusual longitudinal treatment regimen given his/her covariates, the
subject will receive a large weight. Applied to our HIV example, it is likely
that the majority of patients will switch therapy quickly following a decline
in their CD4 T-cell counts. A subject that did not switch therapy despite a
recent decline in CD4 T-cell count would thus have a small predicted prob-
ability of receiving his/her observed treatment, and receive a large weight.
The goal of the weighting process is to create a new dataset, in which the ef-
fect of exposure time on outcome is no longer confounded. The least squares
estimator is then calculated using this weighted dataset.
In addition to the assumptions discussed above, the IPTW estimator
relies on the additional assumption that for each time point, for every sub-
population defined by treatment and covariate history up to that time point,
every possible treatment that is compatible with the treatment history up till
that time point must have positive probability of occurring (Experimental
Treatment Assignment assumption: For all possible A¯(t−1), L¯(t)), P (A(t) =
a(t)|A¯(t − 1), L¯(t)) > 0 for all a(t) ∈ a∗(t) : (A¯(t− 1), a∗(t)) ∈ A(t)) In our
example, we assume that all individuals who have not yet switched treatment
at each time point have some positive probability of both remaining on their
current treatment and of switching to a new treatment at that time point,
8
http://biostats.bepress.com/ucbbiostat/paper173
regardless of their covariate values.
The first step in implementing the IPTW estimator is to assume a model
for the treatment mechanism, a predictive model of treatment at each time
point t, given the observed past up till that time point.
g(A(t)|A¯(t− 1), L¯(t)), t = 0, .., K (4)
The parameters of the model can be estimated using maximum likelihood.
In specifying the treatment mechanism, one can choose to specify a separate
model for treatment at each time point, or have a single model for all time
points, with or without including time as a covariate in the model. For
example, one might choose a single logistic regression model for the treatment
decision (switch therapy or not) made at every time point t,
P (A(t) = 1 | A(t−1) = 1, CD4(t)) = 1
1 + exp−(θ0+θ1(CD4(t))+θ2(t))
, t = 0, ..., K
(5)
where CD4(t) CD4 T-cell count at time t. If we believe the model (5), we
assume that the decision about whether or not to switch treatment at each
time point is made based on a patient’s most recent CD4 T-cell count and
the time that has elapsed. Recall that a subject switches therapy only once;
once a subject switches, he/she is no longer at risk of switching in the future.
Thus, when fitting our model of the probability of staying on therapy at a
given time point(A(t) = 1), we condition on not having already switched
before that time point (A(t− 1) = 1).
For the IPTW estimator to be consistent, the estimate of the treatment
mechanism must be consistent. In addition, enough covariates must be in-
cluded in the treatment model so that outcome is independent of treatment
assignment conditional on the variables in the model (or in other words, there
must not be additional confounders that do not appear in the model of the
treatment mechanism).
For each time point j = 0, ..., K + 1 − m, the model of the treatment
mechanism (5) is used to estimate the denominator of the j-specific weight:∏j+m−1
l=j g(A(l) | A¯(l − 1), L¯(l)). In our example, for subjects who do not
switch therapy before the outcome is measured m months later, the denom-
inator of the j-specific weight is
∏j+m−1
l=j P (A(l) = 1 | A(l− 1) = 1, CD4(l)).
For subjects who have not switched therapy by time j, but who switch at
some point T = j + C(j) before the outcome is measured (C(j) < m), the
denominator of the j-specific weight is
9
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(1 − P (A(T ) = 1 | A(T − 1) = 1, CD4(T )))∏T−1l=j P (A(l) = 1 | A(l − 1) =
1, CD4(l)). For subjects that have already switched therapy by time j, the
denominator of the j-specific weight is always 1.
For example, suppose we have a subject who switched therapy at time
point 6. To model the weight for this subject corresponding to j = 5, C(j) =
1, one begins by using the model of the treatment mechanism and the sub-
ject’s covariate and treatment history to estimate the probability that the
subject followed his/her observed treatment history beginning at time point
5. Using the model described above (5), one first estimates the probability
that the subject did not switch therapy at time 5, given the subject’s CD4 T-
cell count at time 5 and the elapsed time (P (A(5) = 1 | A(4) = 1, CD4(5)).
One then uses the observed CD4 T-cell count at time 6, CD4(6), and the
elapsed time, t = 6, to estimate the probability of switching therapy at time
6 (1− P (A(6) = 1 | A(5) = 1, CD4(6))). By repeating this process for each
time point until a subject switches, one generates an estimate of the proba-
bility of the subject receiving his/her observed treatment at each time point
(after a subject switches, the probability of receiving his/her observed treat-
ment is 1); the product of these probabilities provides an estimate of the
probability of the subject receiving his/her observed treatment over time,
from time point j until the outcome is measured.
Choice of a numerator for the weights will not affect the consistency of
the IPTW estimator, as long as the numerator is only a function of treatment
history and baseline covariates at time j. A standard choice of numerator is
g∗(A(j, j +m − 1) | V (j)) ≡ ∏j+m−1l=j g∗(A(l) | A¯(l − 1), V (j)),. To estimate
this numerator for each subject’s j-specific weights one simply fits a model of
the treatment decision at each time point t = j, ..., K, analogous to the model
of the treatment mechanism fit for the denominator, but now including only
those covariates contained in the subset of baseline measurements at time
j. Applied to the treatment mechanism in our HIV example, (5), the model
used to generate the numerators would be a function of the elapsed time,
t (the treatment mechanism specified in (5) does not include any baseline
covariates, V (j)).
Finally, once each subject has been assigned a set ofK+1−m weights, the
simple least squares estimator of the parameter of interest can be estimated
on the pooled data, using standard software, with each subject contributing
K+1−m weighted lines of data. For example, in estimating the parameters




• An indicator that the subject remained on non-suppressive therapy at
the previous time point (I(A(j − 1) = 1))
• Elapsed time since loss of suppression occurred (j)
• Remaining time until the subject either switched therapy or the out-
come was measured (C(j))
• The subject’s current viral mutations (S(j))
• The subjects CD4 T-cell count 4 months later (Y (j +m))
• The subject’s j-specific weight One then simply runs a weighted least
squares regression on the pooled data, providing the software with the
weights.
6 Discussion.
The history-adjusted marginal structural models presented in this paper rep-
resent an important generalization of marginal structural model methodol-
ogy. Marginal structural models are well-established as powerful tools for
causal inference, particularly in the the setting of longitudinal data. In this
article we have introduced an extension of marginal structural models to iden-
tify and estimate time-dependent causal effect modification. The methods
outlined in this paper demonstrate how history-adjusted marginal structural
models can be implemented using standard software. We believe this method
will prove to be an extremely useful tool for using observational data to im-
prove clinical decision-making based on time-varying covariates.
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